Characteristics of AML patients and healthy controls
| . | Initial samples (n = 21) . | Relapse samples (n = 15) . | Healthy BM donors (n = 13) . |
|---|---|---|---|
| Age (y), mean (range) | 7.5 (0.4-16.6) | 8.5 (1.9-17.1) | 8.8 (1.7-19.1) |
| Gender (male/female) | 11/10 | 6/9 | 4/9 |
| Age at initial diagnosis (y), mean (range) | 7.5 (0.4-16.6) | 6.3 (0.4-16.5) | — |
| AML blasts frequency by flow cytometry (%) | 68 (40-96) | 51 (20-80) | — |
| Future relapse, n (%) | 7 (33.3) | — | |
| Time to relapse (y), mean (range) | 1.2 (0.2-1.8) | — | |
| Death, n (%) | 3 (14.3) | 7 (46.7) | — |
| Monitoring period (y), mean (range) | 7.0 (0.8-14.4) | 7.3 (0.9-14.4) | — |
| FAB phenotype, n (%) | |||
| M0 | 1 (4.8) | 1 (6.7) | — |
| M1 | 2 (9.5) | 0 (0) | — |
| M2 | 5 (23.8) | 3 (20.0) | — |
| M3 | 0 (0) | 0 (0) | — |
| M4 | 6 (28.6) | 4 (26.7) | — |
| M4eo | 1 (4.8) | 2 (13.3) | — |
| M5 | 3 (14.3) | 4 (26.7) | — |
| M6 | 1 (4.8) | 0 (0) | — |
| M7 | 1 (4.8) | 0 (0) | — |
| Unknown | 1 (4.8) | 1 (6.7) | — |
| Cytogenetic aberrations, n (%) | |||
| Normal karyotype | 5 (23.8) | 4 (26.7) | — |
| t(8;21) | 5 (23.8) | 2 (13.3) | — |
| Inv(16) | 0 (0) | 2 (13.3) | — |
| Trisomy 8 | 1 (4.8) | 0 (0) | — |
| Del(9q) | 1 (4.8) | 0 (0) | — |
| t(6;9) | 1 (4.8) | 0 (0) | — |
| Del(17p)/p53 | 1 (4.8) | 0 (0) | — |
| Trisomy 6 + 7 | 1 (4.8) | 0 (0) | — |
| t(7;12)(q36, p13) + trisomy 19 | 0 (0) | 4 (26.7) | — |
| Del(12p) | 0 (0) | 1 (6.7) | — |
| Other abnormalities | 3 (14.3) | 0 (0) | — |
| Unknown | 3 (14.3) | 2 (13.3) | — |
| Mutations, n (%) | |||
| FLT3.ITD | 2 (9.5) | 1 (6.7) | — |
| KMT2A fusion | 4 (19.0) | 1 (6.7) | — |
| . | Initial samples (n = 21) . | Relapse samples (n = 15) . | Healthy BM donors (n = 13) . |
|---|---|---|---|
| Age (y), mean (range) | 7.5 (0.4-16.6) | 8.5 (1.9-17.1) | 8.8 (1.7-19.1) |
| Gender (male/female) | 11/10 | 6/9 | 4/9 |
| Age at initial diagnosis (y), mean (range) | 7.5 (0.4-16.6) | 6.3 (0.4-16.5) | — |
| AML blasts frequency by flow cytometry (%) | 68 (40-96) | 51 (20-80) | — |
| Future relapse, n (%) | 7 (33.3) | — | |
| Time to relapse (y), mean (range) | 1.2 (0.2-1.8) | — | |
| Death, n (%) | 3 (14.3) | 7 (46.7) | — |
| Monitoring period (y), mean (range) | 7.0 (0.8-14.4) | 7.3 (0.9-14.4) | — |
| FAB phenotype, n (%) | |||
| M0 | 1 (4.8) | 1 (6.7) | — |
| M1 | 2 (9.5) | 0 (0) | — |
| M2 | 5 (23.8) | 3 (20.0) | — |
| M3 | 0 (0) | 0 (0) | — |
| M4 | 6 (28.6) | 4 (26.7) | — |
| M4eo | 1 (4.8) | 2 (13.3) | — |
| M5 | 3 (14.3) | 4 (26.7) | — |
| M6 | 1 (4.8) | 0 (0) | — |
| M7 | 1 (4.8) | 0 (0) | — |
| Unknown | 1 (4.8) | 1 (6.7) | — |
| Cytogenetic aberrations, n (%) | |||
| Normal karyotype | 5 (23.8) | 4 (26.7) | — |
| t(8;21) | 5 (23.8) | 2 (13.3) | — |
| Inv(16) | 0 (0) | 2 (13.3) | — |
| Trisomy 8 | 1 (4.8) | 0 (0) | — |
| Del(9q) | 1 (4.8) | 0 (0) | — |
| t(6;9) | 1 (4.8) | 0 (0) | — |
| Del(17p)/p53 | 1 (4.8) | 0 (0) | — |
| Trisomy 6 + 7 | 1 (4.8) | 0 (0) | — |
| t(7;12)(q36, p13) + trisomy 19 | 0 (0) | 4 (26.7) | — |
| Del(12p) | 0 (0) | 1 (6.7) | — |
| Other abnormalities | 3 (14.3) | 0 (0) | — |
| Unknown | 3 (14.3) | 2 (13.3) | — |
| Mutations, n (%) | |||
| FLT3.ITD | 2 (9.5) | 1 (6.7) | — |
| KMT2A fusion | 4 (19.0) | 1 (6.7) | — |
FAB, French‐American‐British (Cooperative Group classification).21